In vivo targeting of E. coli with vancomycin-arginine.

In vivo targeting of E. coli with vancomycin-arginine. Antimicrob Agents Chemother. 2021 Jan 19;: Authors: Neville LF, Shalit I, Warn PA, Scheetz MH, Sun J, Chosy MB, Wender PA, Cegelski L, Rendell JT Abstract The ability of vancomycin-arginine (V-r) to extend the spectrum of activity of glycopeptides to gram-negative bacteria was investigated. Its MIC towards E. coli including β-lactamase expressing Ambler classes A, B, and D was 8-16μg/ml. Addition of 8×MIC V-r to E. coli was acutely bactericidal and associated with a low frequency of resistance (< 2.3×10-10). In vivo, V-r markedly reduced E. coli burden by >7 log10 CFU/g in a thigh muscle model. These data warrant further development of V-r in combatting E. coli, including resistant forms. PMID: 33468474 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research